Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Tolerability of the triptans: clinical implications.

Giuseppe Nappi1, Giorgio Sandrini, Grazia Sances

  • 1University Centre for Adaptive Disorders and Headache, IRCCS C. Mondino Foundation, University of Pavia, Italy. giuseppe.nappi@mondino.it

Drug Safety
|January 22, 2003
PubMed
Summary

Triptans are safe and well-tolerated migraine treatments when used correctly. While adverse events like

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Is achieving higher standards in real-world migraine care feasible with anti-CGRP monoclonal antibodies preventive therapies?: Insights from the EUREkA cohort.

Cephalalgia : an international journal of headache·2026
Same author

Beyond Pain: Psychological Profiles in Chronic Migraine Compared With Fibromyalgia and Their Comorbidity.

Annals of the New York Academy of Sciences·2026
Same author

Long-Term Effectiveness and Persistence Factors of Anti-CGRP Monoclonal Antibodies in Migraine: 2-Year Results From the EUREkA Cohort.

Neurology·2026
Same author

Translation and validation of the Migraine Interictal Burden Scale (MIBS-4) in an Italian clinical cohort.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·2026
Same author

Long-Term Effectiveness and Persistence Factors of Anti-CGRP Monoclonal Antibodies in Migraine: 2-Year Results From the EUREkA Cohort.

Neurology·2026
Same author

miR-382-5p and miR-34a in migraine: Expression in monocytes and a post-hoc exploratory comparison with expression in peripheral blood mononuclear cells.

Cephalalgia : an international journal of headache·2025

Area of Science:

  • Neurology
  • Pharmacology

Background:

  • Triptans are a novel class of drugs widely used for acute migraine treatment.
  • Extensive research has evaluated the safety and tolerability of triptans since sumatriptan's market introduction.

Purpose of the Study:

  • To consolidate findings on the safety and tolerability of triptans in a large patient population.
  • To identify and characterize common adverse events associated with triptan therapy.

Main Methods:

  • Review of clinical trial data.
  • Analysis of postmarketing surveillance studies.

Main Results:

  • Triptans are confirmed as safe and well-tolerated in a large patient cohort.
  • Adverse events are generally mild, with few discontinuations; common events include 'triptan symptoms'.
  • Chest symptoms are infrequent and rarely cardiac-related; CNS effects like somnolence warrant further investigation regarding causality.

Conclusions:

  • Triptans demonstrate a favorable safety profile for migraine management.
  • Potential risks, such as drug overuse in frequent migraineurs and drug interactions, require consideration.
  • No teratogenic risk has been identified in pregnant women using triptans.

Related Experiment Videos